

March 3, 2023



# Avalon GloboCare to Participate in the 35th Annual Roth Conference

FREEHOLD, N.J., March 03, 2023 (GLOBE NEWSWIRE) -- **Avalon GloboCare Corp.** (“**Avalon**” or the “**Company**”) (**NASDAQ: ALBT**), a leading global developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced that it has been invited to participate in the 35<sup>th</sup> Annual Roth Conference being held on March 13 and 14, 2023.

Luisa Ingargiola, Chief Financial Officer of Avalon, will be available for one-on-one and small group investor meetings during those days. The Conference will be held at The Ritz Carlton, Laguna Niguel located in Dana Point, California.

To arrange a 1-on-1 please email [oneononerequests@roth.com](mailto:oneononerequests@roth.com), or contact your Roth sales team. For more information about the event or questions about registration, please contact your Roth representative.

## **About Avalon GloboCare Corp.**

Avalon GloboCare Corp. (NASDAQ: ALBT) is a clinical-stage biotechnology company dedicated to developing and delivering innovative, transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics. For more information about Avalon GloboCare, please visit [www.avalon-globocare.com](http://www.avalon-globocare.com).

For the latest updates on Avalon GloboCare’s developments, please follow our twitter at [@avalongc\\_avco](https://twitter.com/avalongc_avco)

## **Forward-Looking Statements**

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, including statements regarding the transaction and the business of Laboratory Services. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (<http://www.sec.gov>). In addition to these factors, actual future performance, outcomes, and results may differ

materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.

**Contact Information:**

Avalon GloboCare Corp.  
4400 Route 9, Suite 3100  
Freehold, NJ 07728  
PR@Avalon-GloboCare.com

**Investor Relations:**

Crescendo Communications, LLC  
Tel: (212) 671-1020 Ext. 304  
albt@crescendo-ir.com



Source: Avalon GloboCare Corp.